131 related articles for article (PubMed ID: 35342104)
1. Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery.
Aziret M; Subasi O; Bilir C; Tozlu M; Altıntoprak F; Karaman K; Ercan M; Celebi F
Ann Ital Chir; 2022; 92():65-77. PubMed ID: 35342104
[TBL] [Abstract][Full Text] [Related]
2. Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutations†.
Renaud S; Schaeffer M; Falcoz PE; Seitlinger J; Romain B; Voegeli AC; Legrain M; Reeb J; Santelmo N; Rohr S; Brigand C; Olland A; Guenot D; Massard G
Eur J Cardiothorac Surg; 2017 Feb; 51(2):255-262. PubMed ID: 28186237
[TBL] [Abstract][Full Text] [Related]
3. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Michl M; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmueller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Mueller S; Lerch MM; Modest DP; Kirchner T; Jung A; Heinemann V;
Ann Oncol; 2016 Aug; 27(8):1565-72. PubMed ID: 27234640
[TBL] [Abstract][Full Text] [Related]
4. Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes.
Zekri J; Al-Shehri A; Mahrous M; Al-Rehaily S; Darwish T; Bassi S; El Taani H; Al Zahrani A; Elsamany S; Al-Maghrabi J; Sadiq BB
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218784
[TBL] [Abstract][Full Text] [Related]
5. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
6. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
11. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
12. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.
Demircan NC; Dane F; Ozturk MA; Babacan NA; Besiroglu M; Kaya S; Ercelep O; Tanrikulu E; Halil S; Koca S; Alan O; Hasanov R; Yumuk PF
J BUON; 2019; 24(4):1494-1500. PubMed ID: 31646797
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
14. RAS mutation: site of disease and recurrence pattern in colorectal cancer.
Bonnot PE; Passot G
Chin Clin Oncol; 2019 Oct; 8(5):55. PubMed ID: 31597436
[TBL] [Abstract][Full Text] [Related]
15. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
17. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
[TBL] [Abstract][Full Text] [Related]
18. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
[TBL] [Abstract][Full Text] [Related]
19. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
20. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
